Fertility and Sterility
Volume 94, Issue 2 , Pages 764-766, July 2010

Effect of genistein therapy on plasma levels of asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study

  • Ikbal Kaygusuz, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Fatih University, Ankara, Turkey
    • ,
  • Nilgun Ozturk Turhan, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Fatih University, Ankara, Turkey
    • ,
  • Candan Iltemir Duvan, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Fatih University, Ankara, Turkey
    • Corresponding Author InformationReprint requests: Candan Iltemir Duvan, M.D., Fatih University Hospital, Hosdere cad. No. 145, Yukari Ayranci 06540, Ankara, Turkey (FAX: 90-312-441-54-98).
    • ,
  • Cemile Koca, M.D.

      Affiliations

    • Department of Biochemistry, Fatih University, Ankara, Turkey
    • ,
  • Murat Aydin, M.D.

      Affiliations

    • Department of Biochemistry, Fatih University, Ankara, Turkey

Received 14 May 2009; received in revised form 24 September 2009; accepted 27 September 2009. published online 10 December 2009.

The aim of this study was to investigate the effects of pure genistein therapy on asymmetric dimethylarginine in healthy postmenopausal women. Healthy postmenopausal women received pure genistein (n=21) or placebo (n=17) for 6 months, and no statistically significant effects on plasma asymmetric dimethylarginine levels were found with pure genistein treatment.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 I.K. has nothing to disclose. N.O.T. has nothing to disclose. C.I.D. has nothing to disclose. C.K. has nothing to disclose. M.A. has nothing to disclose.

PII: S0015-0282(09)03807-2

doi:10.1016/j.fertnstert.2009.09.057

Fertility and Sterility
Volume 94, Issue 2 , Pages 764-766, July 2010

Article Tools